
Nkarta CEO Paul Hastings at Endpoints' #BIO22 panel (J.T. MacMillan Photography for Endpoints News)
Nkarta breaks silence on CAR-NK therapy for AML after a year, shares tumble
Nkarta hopes using a different chemotherapy regimen ahead of dosing its CAR-NK cell therapy will lead to better results in acute myeloid leukemia patients whose …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.